{"id":155033,"date":"2026-11-19T16:03:22","date_gmt":"2026-11-19T07:03:22","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4882-20261119-01_wp_general_ir\/"},"modified":"2026-11-19T16:03:22","modified_gmt":"2026-11-19T07:03:22","slug":"4882-20261119-01_wp_general_ir","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261119-01_wp_general_ir\/","title":{"rendered":"Summary of Q2 Q&#038;A Including Clinical Results and Partnership Trends for PPMX-T003"},"content":{"rendered":"<p>The company positions expansion of collaborative research agreements as a growth strategy. Master cell bank manufacturing for PPMX-T004 is scheduled to start in January 2027. Of the planned fundraising under the 29th share acquisition rights of approximately 930 million yen, about 700 million yen has been raised. The ASH presentation will inform licensing\/out-licensing decisions, but any deal is up to the partner company. Approval of PTX3 is expected to have a minor impact on results, but details remain undisclosed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4882","jir_company_name":"Perseus Proteomics Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4882-20261119-01.pdf","jir_short_summary":"The company positions expansion of collaborative research agreements as a growth strategy. Master cell bank manufacturing for PPMX-T004 is scheduled to start in January 2027. Of the planned fundraising under the 29th share acquisition rights of approximately 930 million yen, about 700 million yen has been raised. The ASH presentation will inform licensing\/out-licensing decisions, but any deal is up to the partner company. Approval of PTX3 is expected to have a minor impact on results, but details remain undisclosed.","jir_summary":"### Business and Partnership Progress\nAs part of its growth strategy, the company promotes collaboration with external partners, expanding ties including a collaborative research agreement with Kyorin Pharmaceutical and previous collaborations with Asuka Pharmaceutical and Eurus Therapeutics. Going forward, the company aims to maximize business value through collaboration with external partners built on its drug discovery platform.\n\n### Fundraising and R&D Progress\nFundraising through the 29th issuance of share acquisition rights planned for approximately 930 million yen has raised about 700 million yen. Master cell bank manufacturing for PPMX-T004 is scheduled to begin in January 2027. Clinical study results will be subject to the licensee's decision, and the ASH presentation will serve as supplemental clinical data. Timing of future fundraising is currently unknown.","jir_financial_highlights":"Planned fundraising via issuance of share acquisition rights: Of the approximately 930 million yen plan, about 700 million yen was raised and completed in June (Unknown)\nPPMX-T004 development costs: 150 million yen (Planned to be incurred from autumn 2026 onward, so expenditures are forthcoming)\nRelease of clinical study results for PPMX-T003: Not listed (Planned to be presented at ASH)","jir_category":"","jir_hashtags":"#PPMX, #CollaborativeResearch, #Fundraising, #ASHEvent","jir_key_figures":"Of the approximately 930 million yen fundraising plan, about 700 million yen was raised and completed in June\nPPMX-T004 development costs of 150 million yen are expected to be incurred from autumn 2026 onward and will be expended going forward\nPPMX-T003 is scheduled for presentation at ASH (licensing decision depends on the partner company)","jir_meta_title":"Perseus Proteomics Inc. - Summary of PPMX Q&A\uff5cNovember 2026","jir_meta_description":"Summary of master cell bank manufacturing start for PPMX-T004, ASH presentation for PPMX-T003, expansion of collaborative research agreements with partners such as Kyorin Pharmaceutical, and fundraising status. Timing of future fundraising is TBD.","jir_og_title":"Summary of PPMX Q&A\uff5cNovember 2026","jir_og_description":"An IR summary outlining expansion of collaborative research agreements, fundraising status, and outlook regarding the ASH presentation. Future prospects depend on partner companies.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60609,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-155033","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Summary of Q2 Q&amp;A Including Clinical Results and Partnership Trends for PPMX-T003 - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261119-01_wp_general_ir\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261119-01_wp_general_ir\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261119-01_wp_general_ir\/\",\"name\":\"Summary of Q2 Q&A Including Clinical Results and Partnership Trends for PPMX-T003 - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-19T07:03:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261119-01_wp_general_ir\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261119-01_wp_general_ir\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261119-01_wp_general_ir\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Summary of Q2 Q&#038;A Including Clinical Results and Partnership Trends for PPMX-T003\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Summary of Q2 Q&A Including Clinical Results and Partnership Trends for PPMX-T003 - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261119-01_wp_general_ir\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261119-01_wp_general_ir\/","url":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261119-01_wp_general_ir\/","name":"Summary of Q2 Q&A Including Clinical Results and Partnership Trends for PPMX-T003 - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-19T07:03:22+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261119-01_wp_general_ir\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261119-01_wp_general_ir\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4882\/ir\/4882-20261119-01_wp_general_ir\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Summary of Q2 Q&#038;A Including Clinical Results and Partnership Trends for PPMX-T003"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"60609","title":"PERSEUS PROTEOMICS INC","ticker":"4882"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/155033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=155033"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/155033\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=155033"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=155033"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=155033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}